HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Requiring GRAS-Level Safety Standards For NDI Submissions, Experts Say

This article was originally published in The Tan Sheet

Executive Summary

FDA has gradually raised the safety standard for new dietary ingredients above the level intended by DSHEA, according to several experts

You may also be interested in...



CFSAN Addresses AER Duplication, NDI Definition In Developing Guidances

FDA is working on a method to avoid duplication when tracking adverse event reports, according to the director of CFSAN's Division of Dietary Supplement Programs

New NDIs

Pom Wonderful's POMX, Procter & Gamble's psyllium hemicellulose and Exquim's Diosvein are new dietary ingredients recently included in the American Herbal Products Association's NDI Database, the trade group says May 4. While 17 NDIs were added to the database, only POMX, psyllium hemicellulose and Diosvein were filed by FDA to acknowledge their receipt, AHPA says. FDA cites a lack of sufficient information to clearly identify the new ingredient as an example of one objection to the other 14 NDIs, AHPA says. In November several experts said FDA has gradually raised the safety standard for NDIs above the level intended by DSHEA (1"The Tan Sheet" Nov. 13, 2006, p. 11)...

FDA Accomplishes A-List Goals, Will Publish NDI Guidance – CFSAN

FDA will publish guidance documents on new dietary ingredient submissions as part of an effort to update the industry on its premarket notification program, CFSAN announced in an Aug. 18 conference call on its program priorities

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS126177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel